One-quarter of patients in the erenumab group still experienced a migraine attack following administration of CGRP, which exceeds the expected rate of a nocebo response [8.1% (95% CI, 2.5–15.5%)].46 This finding is clinically interesting as one-third of migraine patients do not report a substantial reduction in migraine frequency after treatment with an anti-CGRP receptor mAbs.18,47,48 It is worth mentioning that CGRP receptor blockade did partially mitigate CGRP-induced vasodilation, but there was still a residual vascular response. The gene discussed is CALCA; the disease is migraine disorder.